Decreased KCC2 expression in the human spinal dorsal horn associated with chronic pain and long-term opioid use
- PMID: 40667986
- PMCID: PMC12270282
- DOI: 10.1097/j.pain.0000000000003700
Decreased KCC2 expression in the human spinal dorsal horn associated with chronic pain and long-term opioid use
Abstract
Loss of GABAergic and glycinergic inhibitory efficacy in the spinal dorsal horn is associated with neuropathic pain and opioid-induced hyperalgesia in rodent models. Downregulation of the KCC2 chloride extrusion transporter is a key mechanism underlying this decreased inhibitory efficacy, but to-date there is no evidence supporting or opposing this hypothesis in humans. Here, we demonstrate that KCC2 expression is decreased in superficial dorsal horn neurons of organ donors who died with a documented history of pain, or of long-term opioid use. We show profoundly decreased KCC2 dorsal horn membrane expression in a primary cohort associated with either chronic pain or opioid use, and in a replication cohort of mixed chronic pain and opioid use history. These results show that decreased dorsal horn inhibitory efficacy likely promotes chronic pain in humans and support the development of therapeutics augmenting KCC2 function as a treatment for chronic pain and opioid use disorders.
Keywords: Dorsal horn; KCC2; Neuropathic pain; Opioid use disorder.
Copyright © 2025 International Association for the Study of Pain.
Conflict of interest statement
Conflict of Interest Statement: T.J.P. is a co-founder of and holds equity in 4E Therapeutics, NuvoNuro, PARMedics, Nerveli, and Doloromics. T.J.P. has received research grants from AbbVie, Eli Lilly, Grunenthal, Evommune, Hoba Therapeutics, and The National Institutes of Health. YDK has received grants from Axonis Therapeutics, holds equity and chairs their scientific advisory board. M.S.Y. is a co-founder of and holds equity in NuvoNuro.
References
-
- Coull JA, Beggs S, Boudreau D, Boivin D, Tsuda M, Inoue K, Gravel C, Salter MW, De Koninck Y. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 2005;438(7070):1017–1021. - PubMed
-
- Coull JA, Boudreau D, Bachand K, Prescott SA, Nault F, Sik A, De Koninck P, De Koninck Y. Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain. Nature 2003;424(6951):938–942. - PubMed
-
- Dahlhamer JM, Connor EM, Bose J, Lucas JL, Zelaya CE. Prescription Opioid Use Among Adults With Chronic Pain: United States, 2019. Natl Health Stat Report 2021(162):1–9. - PubMed
-
- De la Luz-Cuellar YE, Rodriguez-Palma EJ, Franco-Enzastiga U, Salinas-Abarca AB, Delgado-Lezama R, Granados-Soto V. Blockade of spinal alpha(5)-GABA(A) receptors differentially reduces reserpine-induced fibromyalgia-type pain in female rats. Eur J Pharmacol 2019;858:172443. - PubMed
-
- Dedek A, Topcu E, Dedek C, McDermott JS, Krajewski JL, Tsai EC, Hildebrand ME. Heterogeneity of synaptic NMDA receptor responses within individual lamina I pain-processing neurons across sex in rats and humans. J Physiol 2024;602(20):5309–5327. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources